R&G PharmaStudies Co., Ltd.

XSEC:301333 Stock Report

Market Cap: CN¥5.6b

R&G PharmaStudies Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

David Wu

Chief executive officer

CN¥1.4m

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownershipn/a
Management average tenureno data
Board average tenureless than a year

Recent management updates

Recent updates


CEO

David Wu (63 yo)

no data

Tenure

CN¥1,436,800

Compensation

Mr. Wu Jie, also known as David, MBA serves as Chairman and General manager of R&G PharmaStudies Co., Ltd. He served as General Manager and Director of Tianfa Petroleum Co., Ltd.


Board Members

NamePositionTenureCompensationOwnership
Jie Wu
Chairman & GMno dataCN¥1.44mno data
Leyan Teng
COO, Senior VP & Directorno dataCN¥680.80kno data
Wei Wang
Deputy GM & Directorno dataCN¥832.00kno data
Shuqi Li
Senior VPno dataCN¥567.50kno data
Feng Li
Independent Directorless than a yearno datano data
Hongbei Zheng
Directorno datano data12.15%
CN¥ 679.5m
Weiguo Zhang
Supervisorno datano datano data
Hong Guan
Supervisory Board Chairmanno datano datano data
Yan Zheng
Supervisorno datano datano data
Qiang Chen
Directorno datano datano data
Wen Sun
Independent Directorless than a yearno datano data
Haohai Shi
Independent Directorless than a yearno datano data

0.5yrs

Average Tenure

55yo

Average Age

Experienced Board: 301333's board of directors are not considered experienced ( 0.5 years average tenure), which suggests a new board.